Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous myeloid dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
The autologous myeloid dendritic cell vaccine is an experimental, patient-specific therapeutic vaccine developed by the Infectious Diseases team at Hospital Clínic de Barcelona (IDIBAPS/HIVACAT program). This cell-based biologic consists of monocyte-derived myeloid dendritic cells (MD-DCs) isolated from the patient and pulsed ex vivo with high doses of heat-inactivated whole autologous HIV-1 virus. As professional antigen-presenting cells, these mature dendritic cells are re-administered to the patient to stimulate HIV-1-specific cellular (T lymphocyte) and humoral immune responses. The primary goal of this immunotherapy is to achieve virologic control in patients with early-stage chronic HIV-1 infection, potentially reducing or eliminating the need for lifelong combination antiretroviral therapy (cART).
- Other names
- autologous dendritic cell vaccineMD-DC vaccineHIV-1 dendritic cell vaccineHIV1 dendritic cell vaccineHIV 1 dendritic cell vaccine
02
Targets
CD28 (Cluster of Differentiation 28)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on autologous myeloid dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous myeloid dendritic cell vaccine.